These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20409441)

  • 41. Emerging approaches to managing alcohol dependence.
    Swift R
    Am J Health Syst Pharm; 2007 Mar; 64(5 Suppl 3):S12-22. PubMed ID: 17322178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
    Baser O; Chalk M; Rawson R; Gastfriend DR
    Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Naltrexone and pharmacy benefit management.
    Harris KM; Thomas C
    J Addict Dis; 2004; 23(4):11-29. PubMed ID: 15339711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of naltrexone in the management of alcohol dependence.
    Garbutt JC
    Curr Pharm Des; 2010; 16(19):2091-7. PubMed ID: 20482515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding US addiction physicians' low rate of naltrexone prescription.
    Mark TL; Kranzler HR; Song X
    Drug Alcohol Depend; 2003 Sep; 71(3):219-28. PubMed ID: 12957340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. County-level access to opioid use disorder medications in medicare Part D (2010-2015).
    Abraham AJ; Adams GB; Bradford AC; Bradford WD
    Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Research to practice: adoption of naltrexone in alcoholism treatment.
    Thomas CP; Wallack SS; Lee S; McCarty D; Swift R
    J Subst Abuse Treat; 2003 Jan; 24(1):1-11. PubMed ID: 12646325
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improving adherence in patients with alcohol dependence: a new role for pharmacists.
    Peterson AM
    Am J Health Syst Pharm; 2007 Mar; 64(5 Suppl 3):S23-9. PubMed ID: 17322179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Understanding Ohio X-Waivered Advanced Practice Registered Nurses' Rate of Naltrexone Prescription for Alcohol Use Disordered Patients.
    Wiggins M; Painter S; Burant C; Juratovac E; Alto K
    J Am Psychiatr Nurses Assoc; 2024; 30(3):613-623. PubMed ID: 36694460
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adoption and use of stand-alone electronic prescribing in a health plan-sponsored initiative.
    Pevnick JM; Asch SM; Adams JL; Mattke S; Patel MH; Ettner SL; Bell DS
    Am J Manag Care; 2010 Mar; 16(3):182-9. PubMed ID: 20225913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders.
    Chokron Garneau H; Venegas A; Rawson R; Ray LA; Glasner S
    J Subst Abuse Treat; 2018 Feb; 85():34-37. PubMed ID: 28527854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
    Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
    JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extended release naltrexone for alcohol use disorders: quasi-experimental effects on mortality and subsequent detoxification episodes.
    Harris AH; Bowe T; Del Re AC; Finlay AK; Oliva E; Myrick HL; Rubinsky AD
    Alcohol Clin Exp Res; 2015 Jan; 39(1):79-83. PubMed ID: 25623408
    [TBL] [Abstract][Full Text] [Related]  

  • 54. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder.
    Ray LA; Bujarski S; Grodin E; Hartwell E; Green R; Venegas A; Lim AC; Gillis A; Miotto K
    Am J Drug Alcohol Abuse; 2019; 45(2):124-140. PubMed ID: 30373394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.
    Litten RZ; Wilford BB; Falk DE; Ryan ML; Fertig JB
    Subst Abus; 2016; 37(2):286-98. PubMed ID: 26928397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patterns of organization and management in private and public substance abuse treatment programs.
    Roman PM; Ducharme LJ; Knudsen HK
    J Subst Abuse Treat; 2006 Oct; 31(3):235-43. PubMed ID: 16996386
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
    Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
    Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Innovation attributes and adoption decisions: perspectives from leaders of a national sample of addiction treatment organizations.
    Knudsen HK; Roman PM
    J Subst Abuse Treat; 2015 Feb; 49():1-7. PubMed ID: 25218918
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs.
    Litten RZ; Falk D; Ryan M; Fertig J
    Alcohol Clin Exp Res; 2014 Jan; 38(1):27-32. PubMed ID: 23889161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-threshold extended-release naltrexone for high utilizers of public services with severe alcohol use disorder: A pilot study.
    Smith-Bernardin S; Rowe C; Behar E; Geier M; Washington S; Santos GM; Euren J; Martin J; Gleghorn A; Coffin PO
    J Subst Abuse Treat; 2018 Feb; 85():109-115. PubMed ID: 29150316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.